NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
20/11/2025
Voltar para busca
Dado oficial do USPTO
CELL THERAPY 360
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: Estados Unidos
Snapshot rápido
CELL THERAPY 360
ST13
US500000088347099Classe
5, 9, 36, 42, 44, 45
Pedido
88347099
Registro
5889482
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
09/12/2025
Tipo de marca
Verbal
Classes Nice
5, 9, 36, 42, 44, 45
Data de depósito
19/03/2019
Data de registro
22/10/2019
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
20/11/2025
Última transação
09/12/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
705
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
03
Localização do titular
Summit, NJ
Examinador
OESTREICHER,SALIMA PARMAR
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
C. C. (pessoa física)
Representantes
Marilyn F. Kelly Bristol-Myers Squibb Company
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 36Classe 42Classe 44Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparationspreparations for use in the treatment of cancer and tumors; pharmaceutical and biological preparations for immunotherapyincluding T Cell therapy
Classe 9
Downloadable computer software enabling patients to manage and access data relating to the treatment of cancer and immunological disorders; downloadable computer application software for use on mobile phones and mobile electronic devices for use in connection with providing medical information in the field of cancer and immunological disorders; downloadable electronic publicationsnewsletters and articles featuring medical information in the field of cancer and immunological disorders; downloadable videos featuring medical information in the field of cancer and immunological disorders; downloadable computer software for application and database integration
Classe 36
Financial administration of patient reimbursement programs; financial administration of medication reimbursement programs and services
Classe 42
Software as a Service (SaaS) services featuring software that allows patients to manage and access data relating to the treatment of cancer and immunological disorders; application service provider (ASP) featuring software for medical affair management and information exchange; providing a website featuring non-downloadable software for medical affair management and information exchange; providing an on-line computer database featuring medical and scientific research information in the field of cancer and immunological disorders that allows for input and collection of scientific and research data and information; medical and scientific research liaison servicesconsulting in the field of scientific research pertaining to clinical trials in the fields of health caremedicinepharmacology and biotechnology; scientific research consultation pertaining to clinical trials; providing medical and scientific research information in the field of clinical trials
Classe 44
Providing medical information; providing health information in the field of oncology and immunological disorders; providing a web site featuring medical information; providing a web site featuring health information in the field of oncology and immunological disorders; providing medical informationconsultancy and advisory services; providing information relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals
Classe 45
Providing patient advocate services in the field of the treatment of diseases and disorders
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
20/11/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
20/11/2025
E815
TEAS SECTION 8 & 15 RECEIVED
04/08/2025
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
22/10/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/12/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/12/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
09/12/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/12/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/12/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/12/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
22/10/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/08/2019
PUBO
PUBLISHED FOR OPPOSITION
06/08/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
17/07/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/06/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
28/06/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
28/06/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
28/06/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
28/06/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/06/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/06/2019
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
21/06/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
01/05/2019
GNSL
LETTER OF SUSPENSION E-MAILED
01/05/2019
CNSL
SUSPENSION LETTER WRITTEN
01/05/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
01/05/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/05/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
01/05/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/05/2019
DOCK
ASSIGNED TO EXAMINER
28/04/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/04/2019
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
30/03/2019
ALIE
ASSIGNED TO LIE
28/03/2019
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
22/03/2019
NWAP
NEW APPLICATION ENTERED
22/03/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CELL THERAPY 360 ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.